www.i-canadianpharmacy.com
- US Toll free:
- Regular US:
- UK:
- Categories list
-
- Alcoholism
- Alzheimer's And Parkinson's
- Analgesics
- Anti-inflammatories
- Antiallergic
- Antibiotics
- Anticonvulsants
- Antidepressants
- Antifungals
- Antiparasitic
- Antivirals
- Arthritis
- Asthma
- Birth Control
- Cancer
- Cardiovascular Diseases
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Care
- Gastrointestinal Tract
- HIV
- Hypertension
- Men's Health
- Mental Disorders
- Migraine
- Muscle Relaxants
- Neurological Disorders
- Obesity
- Osteoporosis
- Respiratory Tract
- Skin Care
- Surgery
- Urinary Tract
- Women's Health
Generic Irbesartan - Avalide, Avapro, Micardis
Generic Avalide
Generic Avalide is a combination medication used to treat high blood pressure. One component belongs to a class of blood pressure medications that prevents the hormone angiotensin II from constricting the blood vessels, thereby allowing blood to flow more freely and keeping blood pressure down. The other component is a diuretic that increases the output of urine, removing excess fluid from the body and thus lowering blood pressure.
$1.79
Buy now!
$0.75
Buy now!
Choose Your language:
- Testimonials
-
Yes, thankyou, I have recieved the order. It arrived barely a week after I placed it, so your logistics is working smoothly. Thank you very much for a swift handling :)
Read more »
- News
-
- FDA approved Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years.
- Considering the information of three randomized, multicenter, double, blind clinical studies and a retrospective analysis of the medical documentation, FDA approved on October 7, 2011 Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years
- The forming, development and monitoring of the pharmaceutical market in USA in September 2011
- In spite of low rates and stagnation of industrial development, the pharmaceutical market shows a dynamical growth
- Sildenafil citrate and pulmonary arterial hypertension
- Pulmonary arterial hypertension Definition “pulmonary arterial hypertension” is related to a group of diseases characterized by: - Progressive increase in pulmonary vascular resistance; - Reduction in pulmonary bloodflow; - High pulmonary artery pressure; - Contractility of the heart right ventricle; - Right ventricular failure
- Fruit and vegetables do not reduce overall cancer risk, review concludes
- Eating lots of fruit and vegetables will do little to reduce your risk of developing cancer, according to a review of a decade of research involving more than a million people
- Common painkillers could be linked to male reproductive disorder
- The use of mild painkillers, such as paracetamol, in pregnancy – previously considered harmless to the baby in the womb – could be a major factor in the rise of male reproductive disorders, according to a study
-
- Teva Reports First Quarter 2012 Results - MarketWatch (press release)
- Proactive Investors USA & CanadaTeva Reports First Quarter 2012 ResultsMarketWatch (press release)Products launched included escitalopram, modafinil, progesterone, irbesartan and irbesartan/HCTZ, quetiapine and olanzapine ODT
- Product launches, Cephalon acquisition drive Teva's Q1 revenues - Drug Store News
- Product launches, Cephalon acquisition drive Teva's Q1 revenuesDrug Store News
- Strong Q1 for Sanofi ahead of challenging nine months - PMLiVE
- Strong Q1 for Sanofi ahead of challenging nine monthsPMLiVEThe French firm lost exclusivity for high blood pressure treatment Avapro (irbesartan) at the end of March, 2012, with its big-selling blood thinner Plavix (clopidogrel) set to follow in May, resulting in an expected drop in earnings per share for 2012
- Generic Plavix debuts in US - PMLiVE
- Generic Plavix debuts in USPMLiVESanofi and BMS are weathering the impact of two major patent expiries each, with BMS set to lose US patent protection for $1
- Sanofi's strong 1st-qtr driven by Genzyme - The Pharma Letter
- The Star-Ledger - NJ
 |
Bookmark this site |
|---|
 |
Subscribe to the News |
|---|
